GlassScriptPhysician profile
Vinh Q Le
NPI 1659346856
$4,519.71
in general payments reported to CMS, 2019-2025
28 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $252 · 2021: $467 · 2022: $455 · 2023: $350 · 2024: $1,400 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,759.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,402.29 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $444.78 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.28 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $272.42 | 2024-2025 | |
| Amarin Pharma, INC. | $269.65 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $246.48 | 2019 | |
| Madrigal Pharmaceuticals | $147.49 | 2025 | Rezdiffra |
| Novo Nordisk INC | $141.41 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $136.77 | 2023-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $121.71 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Viiv Healthcare Company | $108.99 | 2024 | |
| Calliditas Therapeutics US INC. | $99.02 | 2025 | Tarpeyo |
| Exact Sciences Corporation | $91.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaukos Corporation | $89.21 | 2024 | Ce-Marked Kxla System |
| Mannkind Corporation | $89.15 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $82.99 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $64.80 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $62.73 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $60.45 | 2019-2021 | |
| Hologic Sales and Service, LLC | $59.23 | 2021 | |
| Dexcom, INC. | $54.55 | 2024-2025 | Dexcom G6 Transmitter |
| Cranial Technologies, INC | $52.95 | 2019-2023 | Doc Band |
| Edwards Lifesciences Corporation | $33.19 | 2023 | Sapien 3 Ultra Resilia |
| Xeris Pharmaceuticals, INC. | $22.88 | 2025 | Gvoke Hypopen |
| Bard Peripheral Vascular, INC. | $15.31 | 2021 | |
| Sanofi Pasteur INC. | $14.49 | 2019 | |
| Allergan, INC. | $13.98 | 2020 | |
| Seqirus USA INC | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinh Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.